Basic Information
| NavDB ID | NA4647 | |
|---|---|---|
| PubChem CID | 127046252 | |
| ChEMBL ID | CHEMBL3798860 | |
| IUPAC Name | (3S)-3-amino-4-[[(1R,4S,10S,13S,16S,19S,22S,25R,30R,33S,36S,39S,42S,45S,48S,51R,54S,57S,60S,63S,69S,72R,77R,80S,86S,89S,92S,95S)-30-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-22,36,69,95-tetrakis(4-aminobutyl)-16,60-bis(2-amino-2-oxoethyl)-86-benzyl-4-[(2S)-butan-2-yl]-45,92-bis(3-carbamimidamidopropyl)-13,19-bis(carboxymethyl)-42-[(1R)-1-hydroxyethyl]-48-(hydroxymethyl)-39-(1H-imidazol-5-ylmethyl)-33-(1H-indol-3-ylmethyl)-57,80-bis(2-methylpropyl)-89-(2-methylsulfanylethyl)-2,3a,5,11,14,17,20,23,32,35,38,41,44,47,50,53,56,59,62,68,71,78,81,84,87,90,93,96-octacosaoxo-54-propan-2-yl-a,27,28,74,75,99-hexathia-2a,3,6,12,15,18,21,24,31,34,37,40,43,46,49,52,55,58,61,67,70,79,82,85,88,91,94,97-octacosazapentacyclo[49.46.4.225,72.06,10.063,67]trihectan-77-yl]amino]-4-oxobutanoic acid | |
| Molecular Formula | C176H271N51O45S7 |
|
| Molecular Weight | 4046.0 | |
| IC50/EC50* (nM) | >5000 | |
| Target | Nav1.5 | |
| Binding Site | VSDII | |
| Organism | Human | |
| UniProt Name | SCN5A_HUMAN | |
| UniProt ID | Q14524 | |
| SMILES | CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(N)=O)C(C)C)NC(=O)[C@H](Cc2c[nH]c4ccccc24)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC3=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C1=O | |
| Category | Toxins and derivatives | |
| InChI | InChI=1S/C176H271N51O45S7/c1-13-93(10)140-174(272)227-64-35-50-131(227)169(267)213-122(77-137(238)239)158(256)210-119(74-132(183)231)155(253)211-121(76-136(236)237)157(255)200-107(45-25-30-59-180)149(247)217-127-85-277-275-83-125(162(260)202-105(43-23-28-57-178)146(244)208-116(70-97-51-53-100(230)54-52-97)160(258)223-138(91(6)7)170(268)205-112(142(185)240)68-95-36-16-14-17-37-95)219-153(251)117(71-98-78-193-103-41-21-20-40-101(98)103)209-147(245)104(42-22-27-56-177)199-154(252)118(72-99-79-190-88-195-99)214-172(270)141(94(11)229)225-151(249)109(48-33-62-192-176(188)189)201-161(259)123(81-228)215-165(263)128-86-278-279-87-129(167(265)224-140)218-148(246)106(44-24-29-58-179)197-145(243)108(47-32-61-191-175(186)187)198-150(248)110(55-65-273-12)203-152(250)115(69-96-38-18-15-19-39-96)196-134(233)80-194-144(242)113(66-89(2)3)206-164(262)124(216-143(241)102(182)73-135(234)235)82-274-276-84-126(220-166(127)264)163(261)204-111(46-26-31-60-181)173(271)226-63-34-49-130(226)168(266)212-120(75-133(184)232)156(254)207-114(67-90(4)5)159(257)222-139(92(8)9)171(269)221-128/h14-21,36-41,51-54,78-79,88-94,102,104-131,138-141,193,228-230H,13,22-35,42-50,55-77,80-87,177-182H2,1-12H3,(H2,183,231)(H2,184,232)(H2,185,240)(H,190,195)(H,194,242)(H,196,233)(H,197,243)(H,198,248)(H,199,252)(H,200,255)(H,201,259)(H,202,260)(H,203,250)(H,204,261)(H,205,268)(H,206,262)(H,207,254)(H,208,244)(H,209,245)(H,210,256)(H,211,253)(H,212,266)(H,213,267)(H,214,270)(H,215,263)(H,216,241)(H,217,247)(H,218,246)(H,219,251)(H,220,264)(H,221,269)(H,222,257)(H,223,258)(H,224,265)(H,225,249)(H,234,235)(H,236,237)(H,238,239)(H4,186,187,191)(H4,188,189,192)/t93-,94+,102-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,138-,139-,140-,141-/m0/s1 | |
| InChI Key | VWANWFMHXJKMFY-PHGCRLBGSA-N | |
| Article DOI | 10.1021/acs.jmedchem.5b01947 | |
| PMID | 26890998 | |
| Authors | Murray, JK; Long, J; Zou, A; Ligutti, J; Andrews, KL; Poppe, L; Biswas, K; Moyer, BD; McDonough, SI; Miranda, LP | |
| Institution | Amgen Inc | |
Calculated Properties
| Heavy Atom Count | 279 | Computed by RDKit |
|---|---|---|
| Ring Count | 11 | Computed by RDKit |
| Hydrogen Bond Acceptor Count | 58 | Computed by RDKit |
| Hydrogen Bond Donor Count | 54 | Computed by RDKit |
| Rotatable Bond Count | 72 | Computed by RDKit |
| logP | -2.16 | Computed by ADMETlab3.0 |
| logS | -3.23 | Computed by ADMETlab3.0 |
| logD | -0.96 | Computed by ADMETlab3.0 |
| pKa_acidic | 3.90 | Computed by ADMETlab3.0 |
| pKa_basic | 6.92 | Computed by ADMETlab3.0 |
| Blood-Brain Barrier (BBB) | 0.00 | Computed by ADMETlab3.0 |
| Plasma Protein Binding (PPB) | -41.71 | Computed by ADMETlab3.0 |
| T1/2 | 14.17 | Computed by ADMETlab3.0 |